Effects of raloxifene therapy on plasma renin and aldosterone levels and blood pressure in postmenopausal women

Gynecological Endocrinology

Volumn 22, Issue 7, 2006, Pages 376-380

  Morgante, Giuseppe ^a   Delia, Ada ^a   Musacchio, Maria ^a   Severi, F ^a   Petraglia, Felice ^a   De Leo, Vincenzo ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Aldosterone; Blood pressure; Postmenopausal women; Raloxifene; Renin

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CALCIUM ANTAGONIST; FELODIPINE; METOPROLOL; RALOXIFENE; RENIN;

ADULT; ALDOSTERONE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; PLASMA RENIN ACTIVITY; POSTMENOPAUSE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BONE DENSITY; FEMALE; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; POSTMENOPAUSE; RALOXIFENE; RENIN; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33746855037     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590600850300     Document Type: Article

References (25)

1. Mitlak BH, Cohen FJ. Selective estrogen receptor modulators: a look ahead. Drugs 1999;57:653-663.
2. Weryha G, Pascal-Vigneron V, Klein M, Leclere J. Selective estrogen receptor modulators. Curr Opin Rheumatol 1999;11:301-306.
3. Goldfrank D, Haytoglu T, Frishman WH, Mohammad Z. Raloxifene, a new selective estrogen receptor modulator. J Clin Pharmacol 1999;39:767-774.
4. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. J Am Med Assoc 1999;282:637-645.
5. Draper MW. The role of selective estrogen receptor modulators (SERMs) in postmenopausal health. Ann N Y Acad Sci 2003;997:373-377.
6. Clemett D, Spencer CM. Raloxifene: a review of its use in postmenopausal osteoporosis. Drugs 2000;60:379-411.
7. Clarkson TB. Raloxifene revisited. Fertil Steril 2002;77:445-447.
8. Cagnacci A, Arangino S, Renzi A, Zanni AL, Volpe A. Raloxifene does not influence flow-mediated endothelium-dependent and endothelium-independent vasodilatation of osteopenic postmenopausal women. Am J Obstet Gynecol 2003;188:313-317.
9. Simoncini T, Varone G, Fornari L, Mannella P, Luisi M, Labrie F, Genazzani AR. Genomic and nongenomic mechanisms of nitric oxide synthesis induction in human endothelial cells by a fourth-generation selective estrogen receptor modulator. Endocrinology 2002;143:2052-2061.
10. De Leo V, la Marca A, Morgante G, Lanzetta D, Setacci C, Petraglia F. Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women. Am J Obstet Gynecol 2001;184:350-353.
11. Marshall SM. Inhibition of the renin-angiotensin system: added value in reducing cardiovascular and renal risk? Diabet Med 2004;21:1-3.
12. Antikainen R, Jousilahti P, Tuomilehto J. Systolic blood pressure, isolated systolic hypertension and risk of coronary heart disease, strokes, cardiovascular disease and all-cause mortality in the middle-aged population. J Hypertens 1998;16:577-583.
13. Rossi R, Grimaldi T, Origliani G, Fantini G, Coppi F, Modena MG. Menopause and cardiovascular risk. Pathophysiol Haemost Thromb 2002;32:325-328.
14. Hassager C, Riis BJ, Strom V, Guyene TT, Christiansen C. The long-term effect of oral and percutaneous estradiol on plasma renin substrate and blood pressure. Circulation 1987;76:753-758.
15. Oelkers WK. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996;61:166-171.
16. RUTH.
17. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JH, Ockerre J.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
18. Hodges YK, Richer JK, Horwitz KB, Horwitz LD. Variant estrogen and progesterone receptor messages in human vascular smooth muscle. Circulation 1999;99:2688-2693.
19. Losordo DW, Kearney M, Kim EA, Jekanowski J, Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89:1501-1510.
20. Manwaring P, Morfis L, Diamond T, Howes LG. Effects of hormone replacement therapy on ambulatory blood pressure and vascular responses in normotensive women. Blood Press 2000;9:22-27.
21. Weir RJ. When the pill causes a rise in blood pressure. Drugs 1978;16:522-527.
22. Woods JW. Oral contraceptives and hypertension. Hypertension 1988;11:11-15.
23. Nichols M, Robinson G, Bounds W, Newman W, Guillebeaud J. Effect of four oral contraceptives on blood pressure in the pill-free interval. Contraception 1993;47:367-376.
24. Kaplan NM. The treatment of hypertension in women. Arch Intern Med 1995;155:563-567.
25. Cagnacci A, Zanni AL, Volpe A. Administration of raloxifene does not influence 24-hour ambulatory blood pressure of postmenopausal women with osteopenia: a double-blind placebo-controlled study. Am J Obstet Gynecol 2003;188:1278-1282.